Product Description
ENX-205 is a unique 5-HT1A /5-HT2A receptor agonist and D2/D3 receptor antagonist in development for PTSD and other mood disorders. ENX-205 has an excellent pharmacokinetic profile that supports once-daily dosing.4 (Sourced from: https://www.engrail.com/enx-205/)
Mechanisms of Action: 5-HT1A Agonist, 5-HT2A Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Engrail Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07253246 |
ENX-205-001 | P1 |
Recruiting |
Healthy Volunteers |
2026-03-01 |
2025-11-29 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|